Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy

American Heart Journal

Volumn 138, Issue 4 II, 1999, Pages

  Juran, N B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

BLEEDING; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE CLASSIFICATION; FEMORAL ARTERY; HUMAN; NURSING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0032887591     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1999.v138.a100462     Document Type: Conference Paper

References (47)

1. Bittl JA. Advances in coronary angioplasty. N Engl J Med 1996;335:1290-302.
2. Ellis SG, Roubin GS, King SB III, et al. In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 procedures. J Am Coll Cardiol 1988;11:211-6.
3. Detre KM, Holmes DR Jr, Holubkov R, et al. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-50.
4. Stammen F, Piessens J, Vrolix M, et al. Immediate and short-term results of a 1988-1989 coronary angioplasty registry. Am J Cardiol 1991;67:253-8.
5. de Feyter PJ, van den Brand M, Laarman GJ, et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up. Circulation 1991;83:927-36.
6. Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-35.
7. Simpfendorfer C, Belardi J, Bellamy G, et al. Frequency, management and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplasty. Am J Cardiol 1987;59:267-9.
8. Ellis SG, Roubin GS, King SB III, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77:372-9.
9. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 1990;82:1193-202.
10. Myler RK, Shaw RE, Stertzer SH, et al. Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol 1992;19:1641-52.
11. de Feyter P, Ruygrok PN. Coronary intervention: risk stratification and management of abrupt coronary occlusion. Eur Heart J 1995;16(suppl L):L97-L103.
12. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
13. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
14. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
15. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
16. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
17. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
18. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998;97:2386-95.
19. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
20. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
21. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
22. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-90.
23. Coller BS, Peerschke EI, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983;72:325-38.
24. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64.
25. Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665-71.
26. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-8.
27. Faulds D, Sorkin EM. Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994;48:583-98.
28. REOPRO (abciximab). In: Physicians' desk reference. 53rd edition. Montvale, NJ: Medical Economics Company; 1999. p . 1627-31.
29. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996;28:1643-51.
30. Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-35.
31. Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 1991;614:193-213.
32. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-13.
33. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-7.
34. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80:11B-20B.
35. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-42.
36. AGGRASTAT (tirofiban hydrochloride). In: Physicians' desk reference. 53rd edition. Montvale, NJ: Medical Economics Company; 1999. p . 1721-5.
37. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
38. Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-13.
39. Blankenship JC, Hellkamp AS, Aguirre FV, et al. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am J Cardiol 1998;81:36-40.
40. Blankenship JC, Anderson KM, Demko SL, et al. Decreased vascular access site bleeding after coronary intervention with abciximab in the EPILOG vs the EPIC trial [abstract]. Circulation 1997;96 (suppl I):I-161.
41. Tcheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Am J Cardiol 1997;80:21B-8B.
42. Kleiman NS. Primary and secondary safety endpoints from IMPACT II. Am J Cardiol 1997;80:29B-33B.
43. Brown KJ, Morscher JH, Whitman GR, et al. The incidence and analysis of bleeding and vascular complications following percutaneous coronary interventional procedures [abstract]. Circulation 1993;88(suppl I):I-196.
44. Laughon D, Ax S, Boyington C. From unit-based quality assurance to multidisciplinary continuous quality improvement in the coronary care unit. J Nurs Care Qual 1993;7:19-27.
45. Christensen BV, Iacarella CL, Manion RV, et al. Sandbags do not prevent complications after catheterization [abstract]. Circulation 1994;90(suppl I):I-205.
46. Juran NB, Smith DD, Rouse CL, et al. Survey of current practice patterns for percutaneous transluminal coronary angioplasty. Am J Crit Care 1996;5:442-8.
47. Juran NB, Rouse CL, Smith DD, et al. Nursing interventions to decrease femoral access site bleeding after percutaneous coronary intervention. J Crit Care Nurs 1999 (in press).